Apollo Endosurgery

Apollo Endosurgery, Inc. is a medical technology company, which focuses on the design, development, and commercialization of medical devices to advance gastrointestinal therapeutic endoscopy. It offers Endoscopy, Surgical and Other products. The firm's endoscopy product portfolio consists of the OverStitch Endoscopic Suturing System, the OverStitch Sx Endoscopic Suturing System, and the Orbera Intragastric Balloon System. Its products are used by gastroenterologists and bariatric surgeons in a variety of settings to treat multiple gastrointestinal conditions including closure of acute perforations and chronic fistulas, inadvertent perforation of the GI tract, tissue closure after the removal of abnormal lesions in the esophagus, stomach or colon, the treatment of swallowing disorders, esophageal stent fixation, and obesity. The company was founded by Christopher J. Gostout and Dennis L. McWilliams in 2005 and is headquartered in Austin, TX.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Apollo Endosurgery develops medical devices for the diagnosis and treatment of gastrointestinal diseases. The company’s device-based therapies are an alternative to invasive surgical procedures, thus lowering complication rates and reducing total healthcare costs. Apollo’s products include the X-Tack™ Endoscopic HeliX Tacking System, the OverStitch™ Endoscopic Suturing System, the OverStitch Sx™ Endoscopic Suturing System, and the ORBERA® Intragastric Balloon. Apollo Endosurgery was founded upon the initial work of the Apollo Group, an international think tank of world-renowned gastroenterologists and surgeons from five leading universities (Mayo Clinic, Johns Hopkins, Medical University of South Carolina, University of Texas Medical Branch-Galveston and Chinese University-Hong Kong.)  Disappointed with the pace of innovation in therapeutic flexible endoscopy, the Group assembled in 1998 (Timeline) with the goal to advance the new discipline; their specific focus was the use of long, flexible instruments deployed through a natural orifice in order to diagnose and potentially treat gastrointestinal disorders.

Dublin, Oct. 15, 2024 (GLOBE NEWSWIRE) -- The "Weight Loss Services Market Size, Share and Trends Analysis Report by Function (Fitness Equipment, Surgical Equipment, Services), Payment (Out-of-Pocket, Government, Private), and Region 2024-2030" report has been added to ResearchAndMarkets.com's offering. The global weight loss services market size is anticipated to reach USD 60.48 billion by 2030. The market is projected to grow at a CAGR of 7.6% from 2024 to 2030. Rising cases of obesity and resultant health consciousness along with increased per capita healthcare expenditure are the key factors fueling the market growth. Obesity is among the major health concerns that lead to a number of associated diseases or complications, such as diabetes, Cardiovascular Diseases (CVDs), and cancers. For instance, as per WHO, in 2016, more than 1.9 billion adults were overweight, out of which around 650 million people were obese. Such instances are expected to encourage people to maintain proper health to help lower the risk of such chronic health issues, thereby augmenting market growth. Key companies in the market are focusing on the development of new ways for weight loss, such as Zumba, sports-specific performance training, aquatic exercise classes, and weight loss supplements. For instance, in August 2018, Herbalife International launched Herbalife24 ACHIEVE protein bar, a convenient, energy-providing snack. This product launch may increase the company's popularity among athletes worldwide. Hence, such initiatives are anticipated to drive the market. Weight Loss Services Market Report Highlights

Weight Loss Services Market Analysis Report 2024-2030, Featuring Profiles of Atkins Nutritionals, Precor, Apollo Endosurgery, Johnson Health Tech, Life Fitness, iFIT, Torque Fitness and More

MERIT Trial Selected as 2022 Top Story in Gastroenterology and ASMBS adds Apollo Systems to List of Approved Bariatric Devices AUSTIN, TX / ACCESSWIRE / December 13, 2022 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in minimally invasive medical devices for gastrointestinal and bariatric procedures, announced today that the MERIT trial, published in The Lancet earlier this year(1), was selected as 2022 Top Story in Gastroenterology. (2) Additionally, the American Society for Metabolic and Bariatric Surgery (ASMBS) formally added four Apollo systems to its list of FDA Approved Bariatric Devices on December 5.

Apollo Endosurgery Announces Two Important Milestones in the Advancement of Endoscopic Procedures for Patients Living with Obesity

Wilmington, Delaware--(Newsfile Corp. - December 6, 2022) - Rigrodsky Law, P.A. is investigating Apollo Endosurgery, Inc. ("Apollo") (NASDAQ GM: APEN) regarding possible breaches of fiduciary duties and other violations of law related to Apollo's agreement to be acquired by Boston Scientific Corporation. Under the terms of the agreement, Apollo's shareholders will receive $10.00 per share.To learn more about this investigation and your rights, visit: https://www.rl-legal.com/cases-apollo-endosurgery-inc.To contact Seth D. Rigrodsky or Gina M.

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Apollo Endosurgery, Inc. Buyout

Graybug Vision

Imago Biosciences

Salisbury Bancorp

NEW YORK , Dec. 6, 2022 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Imago BioSciences, Inc. (NASDAQ: IMGO)'s  sale to Merck for $36.00 per share in cash. If you are an Imago shareholder, click here to learn more about your rights and options.

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates IMGO, GRAY, APEN, SAL

New York, New York--(Newsfile Corp. - December 5, 2022) -  Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating Apollo Endosurgery, Inc. (NASDAQ: APEN), relating to its proposed sale to Boston Scientific Corp.

SHAREHOLDER ALERT: The M&A Class Action Firm Announces the Investigation of Apollo Endosurgery, Inc. - APEN

Boston Scientific

Boston Scientific Corporation (BSX) recently announced it is buying Apollo Endosurgery (APEN) for $615 million in cash. This is why.

Why Boston Scientific (BSX) Is Buying Apollo Endosurgery (APEN) For $615 Million In Cash

NEW ORLEANS--( BUSINESS WIRE )--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Apollo Endosurgery, Inc. (NasdaqGM: APEN) to Boston Scientific Corporation (NYSE: BSX). Under the terms of the proposed transaction, shareholders of Apollo will receive only $10.00 in cash for each share of Apollo that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.

APOLLO ENDOSURGERY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Apollo Endosurgery, Inc. - APEN

NEW YORK , Nov. 29, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Apollo Endosurgery, Inc. ("Apollo Endosurgery" or the "Company") (NASDAQ: APEN), in connection with the proposed acquisition of the Company by Boston Scientific Corporation (NYSE: BSX). Under the terms of the merger agreement, the Company's shareholders will receive $10.00 in cash for each share of Apollo Endosurgery common stock owned.

SHAREHOLDER ALERT: Weiss Law Investigates Apollo Endosurgery, Inc.

Boston Scientific Corp.'s BSX, +0.88% $615 million acquisition of Apollo Endosurgery Inc. APEN, +65.50% announced earlier is complementary to the former's endoscopy franchise, as it leverages its gastroenterologist call point while offering the potential for it to expand into surgical endoscopy and bariatric surgery, Needham analysts aid Tuesday. The deal is expected to have no material impact on Boston Scientific's 2023 per-share earnings but to boost it after that.

Buy-rated Boston Scientific's $615 million takeover of Apollo Endosurgery is a positive, says Needham

One of the medical technology sector's most dynamic players is maneuvering to gain a bigger market share. This morning, Boston Scientific (NYSE: BSX ) announced that it is acquiring Apollo Endosurgery (NASDAQ: APEN ).

Apollo Endosurgery (APEN) Stock Soars 65% on Boston Scientific Deal

Apollo Endosurgery Inc (NASDAQ:APEN) stock is soaring, up 63.4% at $9.80 at last glance, after news that Boston Scientific Corp (BSX) will acquire the medical equipment name for $417 million.

Apollo Endosurgery Stock Soars on Buyout Buzz

MILWAUKEE , Nov. 29, 2022 /PRNewswire/ -- Ademi LLP is investigating Apollo Endosurgery (Nasdaq: APEN) for possible breaches of fiduciary duty and other violations of law in its transaction with Boston Scientific.  Click here to learn how to join the action https://www.ademilaw.com/case/apollo-endosurgery-inc or call Guri Ademi toll-free at 866-264-3995.

Shareholder Alert: Ademi LLP investigates whether Apollo Endosurgery, Inc. has obtained a Fair Price in its Transaction with Boston Scientific

NEW YORK--( BUSINESS WIRE )--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Apollo Endosurgery, Inc. (NASDAQ: APEN) to Boston Scientific Corporation for $10.00 per share in cash is fair to Apollo shareholders.

APEN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Apollo Endosurgery, Inc. Is Fair to Shareholders

Boston Scientific Corp. BSX, -0.82% said Tuesday it has agreed to acquire Apollo Endosurgery Inc. APEN, for $10 a share, or about $615 million in cash. The news sent Apollo's stock, which closed Monday at $6, up 61% in premarket trade.

Boston Scientific to acquire Apollo Endosurgery for $615 million in cash

Boston Scientific to acquire Apollo for $10.00 per share in cash AUSTIN, TX / ACCESSWIRE / November 29, 2022 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a leading minimally invasive medical device company for gastrointestinal and bariatric procedures, announced today it has entered into a definitive merger agreement to be acquired by Boston Scientific Corporation ("Boston Scientific"), a global medical technology leader, in an all-cash transaction with an enterprise value of approximately $615 million.[1] This transaction has been unanimously approved by the Apollo Board of Directors.

Apollo Endosurgery to be Acquired by Boston Scientific

Acquisition to expand endoluminal surgery portfolio and add differentiated technologies for endobariatric procedures MARLBOROUGH, Mass. , Nov. 29, 2022 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced it has entered into a definitive agreement to acquire Apollo Endosurgery, Inc. (Nasdaq: APEN) for a cash price of $10 per share, reflecting an enterprise value of approximately $615 million.1 The Apollo Endosurgery product portfolio includes devices used during endoluminal surgery (ELS) procedures to close gastrointestinal defects, manage gastrointestinal complications and aid in weight loss for patients suffering from obesity.

Boston Scientific Announces Agreement to Acquire Apollo Endosurgery, Inc.

OverStitch has new indications for use statement under CE-Mark, including indications for defect closure, stent fixation, endoscopic sleeve gastroplasty and transoral outlet reduction AUSTIN, TX / ACCESSWIRE / November 21, 2022 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in minimally invasive medical devices for gastrointestinal and bariatric procedures, announced today that it has successfully transitioned its legacy products to CE Mark under the European Medical Device Regulation (MDR). The new certificates were issued by British Standards Institute and were received by the company on November 17, 2022.

Apollo Endosurgery Completes Transition to European MDR Requirements for the OverStitch Systems, BIB and Orbera 365 intragastric balloons, and OverTube.

Apollo Endosurgery, Inc. (NASDAQ:APEN ) Q3 2022 Earnings Conference Call November 1, 2022 4:30 PM ET Company Participants Matt Kreps – Investor Relations Chas McKhann – Chief Executive Officer Jeff Black – Chief Financial Officer Conference Call Participants Mathew Blackman – Stifel Matt Hewitt – Craig-Hallum Capital Frank Takkinen – Lake Street Capital Josh Jennings – Cowen Simran Kaur – Piper Sandler Operator Good afternoon, ladies and gentlemen. And welcome to the Apollo Endosurgery Third Quarter 2022 Results Call.

Apollo Endosurgery, Inc. (APEN) Q3 2022 Earnings Call Transcript

Apollo Endosurgery, Inc. (APEN) delivered earnings and revenue surprises of -33.33% and 8.95%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Apollo Endosurgery, Inc. (APEN) Reports Q3 Loss, Tops Revenue Estimates

Grew global revenue 20% GAAP, 24% in constant currency Received FDA authorization for Apollo ESGTM and Apollo REVISETM systems for treating patients with obesity AUSTIN, TX / ACCESSWIRE / November 1, 2022 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in less invasive medical devices for gastrointestinal and bariatric procedures, today announced financial results for the third quarter ended September 30, 2022 and recent corporate highlights. Third Quarter 2022 Selected Financial Results (Numbers in millions, except percentages) Quarter Ended September 30, 2022 Nine Months Ended September 30, 2022 Revenue $ 19.6 $ 55.5 Gross margin 54.9 % 55.9 % Operating expenses $ 17.0 $ 51.2 Non-GAAP adjusted operating expenses $ 15.2 $ 46.2 Operating loss $ (6.3 ) $ (20.1 ) Net loss $ (11.4 ) $ (30.3 ) Non-GAAP adjusted EBITDA $ (3.6 ) $ (13.0 ) Cash, cash equivalents and restricted cash $ 67.9 $ 67.9 Third Quarter and Recent Corporate Highlights Grew third quarter 2022 U.S. revenue by 29% and OUS revenue by 9% (18% in constant currency) over the same period in 2021; Grew third quarter 2022 Endoscopic Suturing System (ESS) revenue 41% (45% in constant currency) over the same period in 2021; Increased third quarter 2022 revenue from the Company's top 10 direct accounts by approximately 80% over the same period in 2021; Secured FDA marketing authorizations for Apollo ESGTM and Apollo REVISETM, new endoscopic systems for treatment of patients with obesity (BMI 30-50 kg/m2); and Announced publication of the landmark MERIT study for the Endoscopic Sleeve Gastroplasty procedure in The Lancet, demonstrating significant, durable weight loss results and an outstanding patient safety profile.

Apollo Endosurgery, Inc. Reports Record $19.6 million Global Revenue in Third Quarter 2022

AUSTIN, TX / ACCESSWIRE / October 18, 2022 / Apollo Endosurgery, Inc. ("Company" or "Apollo") (NASDAQ:APEN), a global leader in next-generation minimally invasive medical devices for gastrointestinal and bariatric procedures, today announced that the Company is scheduled to release financial results for the third quarter ended September 30, 2022 on Tuesday, November 1, 2022, after market close. In conjunction with the release, Apollo will host a live webcast audio call with presentation slides at 3:30 p.m.

Apollo Endosurgery to Report Third Quarter Results on November 1, 2022

Patients undergoing ESG achieved 24% total body weight loss in a bariatric surgery practice in a community setting. AUSTIN, TX / ACCESSWIRE / August 31, 2022 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in minimally invasive medical devices for gastrointestinal and bariatric procedures, announced that the endoscopic sleeve gastroplasty (ESG) procedure was featured in a 2022 Top 10 Paper at the International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO) 2022 World Congress, held August 23-27 in Miami.

Endoscopic Sleeve Gastroplasty (ESG) Procedure Featured as a "Top 10" Paper at the IFSO 2022 World Congress in Miami

Apollo Endosurgery, Inc. (NASDAQ:APEN ) Q2 2022 Earnings Conference Call August 2, 2022 4:30 PM ET Company Participants Matt Kreps - Investor Relations Chas McKhann - Chief Executive Officer Jeff Black - Chief Financial Officer Conference Call Participants Chris Cooley - Stephens Simran Kaur - Piper Sandler Frank Takkinen - Lake Street Capital Matt Hewitt - Craig-Hallum Capital Operator Good afternoon, ladies and gentlemen and welcome to Apollo Endosurgery Second Quarter 2022 Results. At this time all participants have been placed on a listen-only mode and we will open the floor for your questions and comments after the presentation.

Apollo Endosurgery, Inc. (APEN) CEO Chas McKhann on Q2 2022 Results - Earnings Call Transcript

Apollo Endosurgery came in with another strong quarter of top-line growth whilst growing gross margins on the same. The company saw substantial growth in each of its key segments, coupled with regulatory momentum in its Apollo ESG and REVISE series.

Apollo Endosurgery: Collect Shares At A Discount Following Q2 Earnings

Apollo Endosurgery, Inc. (APEN) delivered earnings and revenue surprises of -23.81% and 7.62%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

News for Apollo Endosurgery Stock (APEN)